



Result Update

Q1 FY26

UPL Ltd.

Institutional Research

UPL Ltd.



Chemical | Q1FY26 Result Update

05th August 2025

Steady operational performance despite challenging environment

Result Highlights

The company posted a revenue increase of 1.6% YoY / down 40.8% QoQ to Rs. 92,160 mn, below market expectations of Rs. 106,060 mn. The Revenue growth was modest for the quarter, driven by a 1% price increase and favourable forex impact. UPL reported an annual revenue increase in international geographies such as North America (+24%) and India (+21%), which had a strong performance. However, Latin America (-10%), Europe (-6%) and ROW (-10%) regions declined during the quarter. EBITDA increased 26.8% YoY / down 56.3% QoQ to Rs. 13,960 mn, while EBITDA margin stood at 15.1% (up 300bps YoY) in Q1FY26, owing to improved product mix, better pricing, higher capacity utilisation, and lower input costs. The company reported a financial loss for Q1FY26, at Rs. 176 crores, marking a sharp improvement from losses of Rs. 528 crores, respectively, in the prior year. The loss was driven by specific cost and market factors, partially offset by higher EBITDA and lower finance costs.

Valuation and Outlook

UPL Ltd has reported steady operational performance during the quarter, driven by revenue growth and improved operational performance. The company has reiterated its FY26 guidance of 4–8% revenue growth and 10–14% EBITDA growth, with management indicating that growth will be margin-led and skewed towards the second half of the year. The company expects to benefit from a strong order book, especially in Latin America, for Q2 onwards, improved product mix, higher capacity utilisation, and cost efficiencies, which should sustain the contribution margin gains seen during the quarter. New product launches remain a key growth lever, with ~\$130 million in additional revenues targeted for FY26, primarily in H2FY26. Regional performance is expected to improve, led by a recovery in LATAM, continued robust demand in North America and Europe, and healthy traction in India crop protection, seeds (Advanta), and specialty chemicals (SUPERFORM). Management remains cautiously optimistic for Q2FY26, maintaining focus on deleveraging, disciplined working capital, and operational excellence. Strategic reviews are underway to explore unlocking value across platforms, with an emphasis on sustaining long-term growth visibility.

Sector Outlook Neutral Stock CMP (Rs.) 720 BSE code 512070 NSE Symbol UPL Bloomberg UPLL IN Reuters UPLL. BO


Key Data

Nifty	24,650
52 Week H/L (Rs,)	735/485
O/s Shares (Mn)	844
Market Cap (Rs. bn)	540
Face Value (Rs.)	2

Average Volume

3 months	2,509,160
6 months	2,546,370
1 year	2.542.480

Share Holding Pattern (%)



Key Highlights

Particulars (Rs. Mn.)	Q1FY26	Q1FY25	YoY (%)	Q4FY25	QoQ (%)
Net Sales	92,160	90,670	1.6%	155,730	-40.8%
Gross Profit	50,470	45,470	11.0%	70,220	-28.1%
Gross Margin (%)	54.8%	50.1%	461bps	45.1%	967bps
EBITDA	13,960	11,010	26.8%	31,910	-56.3%
OPM (%)	15.1%	12.1%	300bps	20.5%	-534bps
Net Profit	-1,760	-5,270	NA	10,790	-116.3%
Net Profit Margin (%)	-1.9%	-5.8%	NA	6.9%	-884bps

Source: Company, BP Equities Research

Relative Price Chart



Research Analyst

Prathamesh Masdekar

Prathamesh.masdekar@bpwealth.com 022-61596158

Key Concall Highlights

Latin America Business Outlook:

UPL expects its Latin America business to recover from the Q1FY26 revenue decline, which was impacted by insecticide pricing pressure in Brazil and product phasing shifts from Q1 to Q2. The company is optimistic about Q2 and H2 performance, supported by a strong order book, improved operational efficiencies, adoption of a sell-out model, enhanced customer engagement, and a robust product portfolio. Management anticipates good growth in the region in the second half of the year as seasonal demand picks up and product mix improves.

North America Business Outlook:

In North America, UPL expects continued growth momentum after revenue increases in Q1FY26, driven by strong in-season demand and normal-to-low channel inventories. The outlook remains positive, supported by robust herbicide sales and higher revenue from key fungicides and insecticides such as mancozeb and acephate. Management anticipates steady demand through the year, underpinned by a well-positioned portfolio and favourable market conditions.

Europe Business Outlook:

UPL maintains a positive outlook for its Europe business following Q1FY26 growth driven by higher volumes in key herbicides and strong performance in fungicides such as captan and the biofungicide. The company continues to see robust demand in markets including Germany, Italy, Belgium, and Spain. Despite weather-related headwinds in parts of Europe, management expects steady performance through the year, supported by a diversified portfolio and healthy in-season demand across core product categories.

UPL Sustainable Agri Solutions:

Sustainable Agri Solutions (SAS) delivered a strong performance, driven by a 9% increase in volumes and a 4% improvement in pricing. The growth was supported by robust demand in the domestic crop protection market, successful new product launches and a favourable product mix. Management expects the positive momentum to continue through FY26, aided by further launches in the herbicide, fungicide, and insecticide categories, expansion of farmer engagement initiatives, and higher adoption of sustainable agri practices. SAS is positioned to benefit from improving rural demand, normal monsoon forecasts, and increasing penetration in high-value segments, which should support margin expansion. The business remains a key pillar in UPL's strategy for profitable growth in India.

Advanta Enterprises:


Advanta Enterprises delivered a strong Q1FY26 performance, driven by 12% higher volumes in key crops such as corn (India, Thailand), grain sorghum, and sunflower (Argentina). Management expects the momentum to continue, supported by robust demand, price increases to offset higher production costs, and new market entries and product launches. While Q1 margins were impacted by elevated raw seed procurement costs and lower recovery in some geographies, these are expected to normalise from Q2, aided by improved finished goods inventory and seasonal cost reduction. The outlook remains positive, with Advanta positioned to capture growth in both existing and new markets.

Guidance:

UPL maintained its FY26 guidance of 4–8% revenue growth and 10–14% EBITDA growth over last year, with performance expected to be margin-led and weighted toward the second half of the year. Management anticipates H2 momentum from a strong Latin America order book, ~\$130 million in new product launches, recovery in insecticide demand, and sustained cost efficiencies. The company also expects continued working capital discipline and further balance sheet deleveraging to support long-term growth.


"UPL has several new products in the pipeline that are expected to be launched in the coming quarters and would contribute to revenue in FY26."


Quarterly Snapshots





Revenue Performance by Platforms





Source: Company, Bpwealth Research

		Key Fi	nancials				
YE March (Rs. Mn.)	FY22	FY23	FY24	FY25	FY26E	FY27E	
Net Sales	462,400	535,760	430,980	466,370	5,00,535	5,42,477	
Growth %	19.5%	15.9%	-19.6%	8.2%	7.3%	8.4%	
EBIDTA	95,290	101,960	42,970	71,280	82,340	96,196	
Growth%	14.1%	7.0%	-57.9%	65.9%	15.5%	16.8%	
Net Profit	44,370	44,140	-18,780	8,200	14,810	26,160	
Growth %	27.0%	-0.5%	-142.5%	-143.7%	80.6%	76.6%	
Diluted EPS	52.6	52.3	-22.3	9.7	17.5	31.0	
Key Ratios							
EBIDTA (%)	20.6%	19.0%	10.0%	15.3%	16.5%	17.7%	
NPM (%)	9.6%	8.2%	-4.4%	1.8%	3.0%	4.8%	
ROE (%)	18.0%	16.4%	-7.6%	2.8%	4.8%	7.9%	
ROCE (%)	13.9%	15.1%	2.8%	8.1%	9.8%	12.1%	
P/E (x)	13.7	13.8	-32.3	74.2	41.1	23.2	
EV/EBITDA (x)	7.7	6.9	17.7	9.5	9.1	7.6	
Net Debt/ EBITDA (x)	2.1	1.7	5.5	3.3	2.9	2.2	

Source: Company, Bloomberg Estimates

Research Desk Tel: +91 22 61596158

Institutional Sales Desk Tel: +91 22 61596403/04/05

Disclaimer Appendix

Analyst (s) holding in the Stock: Nil

Analyst (s) Certification:

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001 Phone- +91 22 6159 6464 Fax-+91 22 6159 6160 Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Wealth Management Pvt. Ltd. CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392